Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Osteoporotic Chronic Kidney Disease
NCT02792413Phase 4Terminated
- Sponsor
- CHU Montpellier
- Start
- Nov 2018
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in osteoporosis comparing Denosumab Arm with Placebo Arm (2 arms). Primary endpoint: Relative variation of femoral bone mineral density at 24 months. Started Nov 2018; status: terminated.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02792413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792413.